Top news of February: COVID-19 vaccines, ocular surface disease, FDA approvals, more
Click Here to Manage Email Alerts
Healio compiled the most-read news in allergy, asthma and immunology posted in February.
Highlights included the fight against vaccine disinformation, the impact of COVID-19 vaccine booster shots on delayed onset urticaria, how dupilumab interacts with ocular surface disease, FDA approvals of Tezspire and Cibinqo for new uses, and more.
Q&A: Peter J. Hotez, MD, PhD, DSc, to address vaccine disinformation in AAAAI keynote
As co-director of the Texas Children’s Hospital Center for Vaccine Development, among other positions, Dr. Hotez discussed “Global Vaccines and Vaccinations: The Science vs. the Antiscience” at the 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting in San Antonio. Read more.
COVID-19 vaccine booster shots may cause delayed-onset urticaria
Sixteen patients at a private dermatology practice in Denmark developed delayed-onset urticaria after receiving Pfizer-BioNTech and Moderna boosters, according to Jakob Lillemoen Drivenes, MD, of Vestfold Hospital Trust in Tonsberg, Norway. Read more.
Dupilumab levels high in tears of patients with moderate to severe ocular surface disease
Patients with atopic dermatitis and moderate to severe ocular surface disease treated with dupilumab had higher levels of the biologic in their tears than those with mild or no ocular surface disease, according to a study published in Clinical and Translational Allergy. Also, Kenneth A. Beckman, MD, FACS, of Ohio State University shares his Perspective. Read more.
FDA approves Tezspire prefilled pen for self-administered asthma treatment
The government agency has approved tezepelumab-ekko for self-administration in a prefilled, single-use pen for patients aged 12 years and older with severe asthma, according to a press release from AstraZeneca. Read more.
HAE exacerbations secondary to insurance barriers: A common, yet avoidable, trigger
Stress can trigger hereditary angioedema (HAE), including stress from dealing with insurance companies while trying to get them to cover HAE treatment, Healio Allergy/Asthma Peer Perspective Board Member Douglas H. Jones, MD, FAAAAI, FACAAI, wrote in one of his latest columns. Read more.
Anaphylaxis occurs during up-dosing, maintenance stages of peanut oral immunotherapy
Often caused by avoidable triggers, anaphylaxis may strike children and adolescents during the up-dosing and maintenance stages of peanut OIT, Aikaterini (Katherine) Anagnostou, MD, MSc, PhD, FACAAI, of Texas Children’s Hospital, told Healio. Also, Healio Allergy/Asthma Peer Perspective Board Member Jennifer A. Dantzer, MD, MHS, comments on the study. Read more.
Prevalence of current eczema increasing among children, adolescents
The prevalence of current asthma increased by 0.98% per decade among adolescents and 1.21% per decade among children over a span of 27 years, according to a study from Sinéad Máire Langan, FRCP, MSc, PhD, of the London School of Hygiene and Tropical Medicine, and colleagues. Read more.
‘More than just a positive test’: Psychosocial aspects of food allergies
The two things most affected by food allergy for both patients and caregivers are quality of life and anxiety, Healio Allergy/Asthma Peer Perspective Board Member Douglas H. Jones, MD, FAAAAI, FACAAI, wrote in one of his latest columns, adding that pediatricians should be aware of these effects and screen for them in their patients and in their patients’ caregivers. Read more.
Vacations increase risk for food allergy reactions among children
Trips away from home increased risks for severe accidental reactions among children and adolescents who have food allergies, according to a letter published in Annals of Allergy, Asthma & Immunology. Read more.
FDA approves expanded use of Cibinqo for adolescents with atopic dermatitis
The approval enables the use of once-daily abrocitinib for adolescents aged 12 to 18 years with atopic dermatitis when other systemic drug products are not adequate or advisable, according to a press release from Pfizer. Also, Peter A. Lio, MD, of Northwestern University Feinberg School of Medicine, shares his Perspective. Read more.